Seeking Alpha

Enzon Pharmaceuticals (ENZN) to sell its specialty pharmaceutical business to the sigma-tau...

Enzon Pharmaceuticals (ENZN) to sell its specialty pharmaceutical business to the sigma-tau Group for $300M plus another $27M if it hits certain milestones. ENZN will also retain royalties of 5-10%on incremental net sales above a baseline amount. ENZN is halted.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs